Amide Compounds Inhibit Factor D to Control Complement Pathway
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders mediated by the complement pathway, such as age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, and rheumatoid arthritis, lack effective small molecule inhibitors for Factor D, which is crucial in the alternative complement pathway, leading to inadequate control of inflammatory responses and cellular damage.
Innovation Solution
Development of amide compounds, as described in the patent, which are used to inhibit Factor D, thereby modulating the complement pathway and reducing detrimental complement activity in the body, specifically targeting the alternative, classical, and lectin pathways to treat various inflammatory and immune disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for complement pathway disorders are used, then existing therapeutic options are available, but effective small molecule inhibitors for Factor D are lacking, leading to inadequate control of inflammatory responses
Solution Approach 1:
The patent segments the complement pathway into specific targets (Factor D, Factor B, C3) and develops selective small molecule inhibitors for each, rather than using broad-spectrum complement inhibitors. This allows precise control of inflammatory responses by targeting specific pathways involved in different disorders.
Solution Approach 2:
The patent introduces small molecule compounds as intermediary substances that bind to and inhibit complement factors (Factor D, Factor B, C3). These small molecules serve as mediators between the therapeutic goal (controlling inflammation) and the biological target (complement pathway), providing a new class of drugs with different pharmacological properties from existing biologics.
2Quantity of substance
If the alternative pathway of the complement cascade is overly activated, then potent anaphylatoxins C3a and C5a are produced, but this leads to cellular damage and inflammatory disorders
Solution Approach 1:
The patent applies preliminary action by inhibiting Factor D and Factor B before C3a and C5a can be produced. By blocking the alternative pathway at upstream steps (Factor D cleavage of Factor B, or Factor B binding to C3(H2O)), the patent prevents the formation of C3 convertase and subsequent generation of harmful anaphylatoxins, thereby preventing cellular damage before it occurs.
Solution Approach 2:
The patent extracts or removes the harmful activation step from the complement cascade by selectively inhibiting Factor D or Factor B. This takes out the problematic alternative pathway activation while potentially preserving other complement functions, reducing anaphylatoxin production without completely shutting down the complement system.
3Reliability
If Factor H is non-functional, then the alternative pathway is overly activated, but this leads to increased C-reactive protein and macular degeneration risk
Solution Approach 1:
The patent introduces small molecule inhibitors as intermediary substances that compensate for defective Factor H function. These small molecules bind to and inhibit Factor D or Factor B, serving as a substitute regulatory mechanism when Factor H is non-functional, thereby preventing uncontrolled alternative pathway activation and its harmful consequences.
Solution Approach 2:
The patent changes the regulatory parameter from protein-protein interaction (Factor H binding to C3b) to small molecule-inhibitor interaction (small molecule binding to Factor D or Factor B). This parameter change provides an alternative control mechanism that can compensate for Factor H deficiency and prevent macular degeneration.
4Reliability
If eculizumab is used to treat PNH, then complement-mediated hemolysis is reduced, but patients remain anemic and require lifelong intravenous injections
Solution Approach 1:
The patent develops small molecule inhibitors that can be administered orally or via shorter-acting routes, replacing the need for lifelong intravenous injections of eculizumab. Small molecules have different pharmacokinetic properties, allowing for less frequent dosing and more convenient administration, while maintaining therapeutic efficacy in PNH treatment.
Solution Approach 2:
The patent substitutes the mechanical delivery system (intravenous injection) with alternative administration routes (oral, subcutaneous). Small molecule compounds can be formulated for oral delivery, eliminating the need for invasive injection procedures and improving patient quality of life while maintaining treatment efficacy.
5Reliability
If complement pathway inhibition is achieved, then inflammatory responses are reduced, but selective inhibition of Factor D provides better control over alternative pathway activation
Solution Approach 1:
The patent segments the complement system into distinct targets (Factor D, Factor B, C3) and develops selective inhibitors for each. By segmenting the inhibition strategy, the patent achieves reliable control over alternative pathway activation through Factor D selectivity, while avoiding unnecessary inhibition of other complement pathways that might be beneficial for host defense.
Solution Approach 2:
The patent applies local quality by creating inhibitors with high specificity for Factor D's unique active site, rather than using broad-spectrum complement inhibitors. This localized, precise inhibition at the Factor D level provides better control over alternative pathway activation while preserving classical and lectin pathway functions that remain important for immune defense.
Data Source
AI summary
Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an amide substituent (R32) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein are capable of reducing the excessive activation of complement.